Listing & Compliance Notices

Innoviva, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(a)(2), 5605(c)(4)).

“August 2, 2023, Innoviva, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, due to Dr. Deborah L. Birx’s previously disclosed resignation from the Company’s Board of Directors (the “Board”), the Company is not in compliance with Nasdaq’s audit committee composition requirements, as set forth in Nasdaq Listing Rule 5605, which requires that the Audit Committee of the Board (the “Audit Committee”) be comprised of at least three “independent directors” (as defined in Nasdaq Listing”

REGIONAL HEALTH PROPERTIES, INC received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).

“August 1, 2023, the Company received a letter (the “ Acceptance Letter ”) from the NYSE American notifying the Company that the Plan was accepted. The NYSE American has granted the Company a plan period through November 10, 2024 to regain compliance with the continued listing standards. If the Company is not in compliance with the continued listing standards by that date or if the Company does not make progress consistent with the Plan during the plan period, the NYSE American may commence delisting procedures. The Company’s common stock, no par value per share (the “ Common Stock ”), and Seri”

Peraso Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“August 1, 2023, the Company received written notification from the Listing Qualifications Department of Nasdaq, granting the Company’s request for a 180-day extension to regain compliance with the Bid Price Rule. The Company now has until January 29, 2024 to meet the requirement. If at any time prior to January 29, 2024, the bid price of the Common Stock closes at $1 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule during the additional 180-day extension”

Forward Industries, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 31, 2023, Forward Industries, Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) by failing to maintain a minimum bid price for its common stock of at least $1.00 per share for 30 consecutive business days. According to the letter, the Company has a 180-calendar day grace period to regain compliance with the Rule (the “Grace Period”), subject to a potential 180 calendar day extension, as described below. To regain compliance, the Company’s common stock must have a mi”

EBET, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(iii)).

“July 31, 2023, the Company was notified by the Staff that it had determined that the Company’s common stock had a closing bid price of $0.10 or less for ten consecutive trading days from July 17, 2023 through July 28, 2023. Accordingly, since the Company was subject to the provisions set forth under Listing Rule 5810(c)(3)(A)(iii), the Staff had determined to delist the Company’s securities from The Nasdaq Capital Market. The Staff letter stated that unless the Company requests an appeal of the Staff’s determination, trading of the Company’s common stock will be suspended at the opening of bus”

Transcode Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5815(a)(2)).

“that the Staff had determined not to accept the Company’s Compliance Plan, that the Company’s request for an extension had been denied, and that the Company’s common stock was subject to delisting from the Nasdaq Capital Market (the “Delisting Determination”). In accordance with Nasdaq Listing Rule 5815(a)(2), the Company was provided with seven calendar days, or until August 2, 2023, to request a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Delisting Determination. The Company subsequently submitted a request for a hearing to Nasdaq, and on August 2, 2023, was notified”

eFFECTOR Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 31, 2023, eFFECTOR Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Stock Market staff indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until January 29, 2024, to regain compliance. The letter states that the Nasdaq staff will provide written”

PaxMedica, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“August 2, 2023, PaxMedica, Inc. (the “Company”) received a written notification (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”), indicating that the Company was not in compliance with the minimum closing bid price requirement set forth in the Nasdaq Listing Rules for The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based”

Taysha Gene Therapies, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(A)).

“August 3, 2023, Taysha Gene Therapies, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The Notice has no effect at this time on the listing of the Company’s common stock (the “Common Stock”), which continues to trade on The Nasdaq Global Select Market under the symbol “T”

HOOKIPA Pharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“PA Pharma Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The notice from Nasdaq has no immediate effect on the listing of the Company’s common stock, and the common stock will continue to be listed on the Nasdaq Global Select Market under the s”

Greenlane Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C), 5810(c)(3)(D)).

“August 3, 2023, Greenlane Holdings, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer is in compliance with Nasdaq Listing Rule 5450(b)(1)(C) because the market value of the Company’s publicly held shares of Class A common stock, par value $0.01 per share (the “Class A common stock”), has fallen below the $5.0 million minimum required for continued listing on the Nasdaq Global Market for a period of at least 30 consecutive business days. Nasdaq calculates publicly held share”

IMAC Holdings, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“August 3, 2023, the Company submitted a plan to Nasdaq to grant the Company an extension of time until November 27, 2023 to provide evidence of compliance with the Minimum Equity Rule, and by filing this Current Report on Form 8-K, which includes (1) disclosure of Nasdaq’s deficiency letter and the specific deficiency or deficiencies cited; (2) a description of the completed transaction or event that enabled the Company to satisfy the stockholders’ equity requirement for continued listing; (3) an affirmative statement that, as of the date of the report, the Company believes it has regained com”

BIOTRICITY INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“August 1, 2023, Biotricity Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the $35 million minimum requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq rules, the Company”

HeartSciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“August 2, 2023, Heart Test Laboratories, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, based on the closing bid price for the previous 30 consecutive business days, the listing of the Company’s shares of common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”). The letter from Nasdaq has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. In accor”

CEMTREX INC received a nasdaq delisting notice notice regarding minimum bid price.

“July 25, 2023, the Company received a Notice of Staff Determination from the Listing Qualifications Department of Nasdaq notifying the Company that its Series 1 Preferred Stock had not gained compliance and would be suspended from trading at the opening of business on August 3, 2023. The Company has requested a hearing regarding the delisting which will stay the suspension and filing of Form 25-NSE with the Securities and Exchange Commission (the “SEC”). On July 25, 2023, the Company received notification that it had been granted a hearing on September 14, 2023. The Company intends to continue”

Mobiquity Technologies, Inc. received a nasdaq extension granted notice regarding stockholders equity.

“July 31, 2023, Mobiquity Technologies, Inc (the “Company”) was notified that the Hearing Panel of The Nasdaq Stock Market has given a grace period until October 31,2023 to regain compliance of the bid price of its common stock closing at $1.00 per share or more for a minimum of ten consecutive business days and a grace period until November 14, 2023 to regain shareholder equity of at least $2.5 million. In order to meet the minimum bid requirement, we have filed a certificate of amendment to our restated certificate of incorporation to effectuate a reverse stock split of 1-for-15 shares of our”

Mobiquity Technologies, Inc. received a nasdaq extension granted notice regarding minimum bid price.

“July 31, 2023, Mobiquity Technologies, Inc (the “Company”) was notified that the Hearing Panel of The Nasdaq Stock Market has given a grace period until October 31,2023 to regain compliance of the bid price of its common stock closing at $1.00 per share or more for a minimum of ten consecutive business days and a grace period until November 14, 2023 to regain shareholder equity of at least $2.5 million. In order to meet the minimum bid requirement, we have filed a certificate of amendment to our restated certificate of incorporation to effectuate a reverse stock split of 1-for-15 shares of our”

Zoomcar Holdings, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(b)(1)(A), 5605(d)(2), 5605(c)(4)).

“July 28, 2023, Innovative International Acquisition Corp. (the “Company”) received a written notice (the “Letter”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that, as a result of the resignation of Valarie Sheppard, a member of the IOAC Board, the Company is not in compliance with Nasdaq’s independent director, compensation and audit committee requirements as set forth in Listing Rule 5605. The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s secur”

Kaival Brands Innovations Group, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“August 1, 2023, Nasdaq notified the Company that its has received a 180-day extension to comply with the Bid Price Rule until January 29, 2024, by which date the Company must evidence compliance with the Bid Price Rule for at least ten (10) consecutive business days. If compliance cannot be demonstrated by January 29, 2024, Nasdaq will provide written notification to the Company that its common stock will be delisted. In the event of such a notification, the Company may appeal Nasdaq’s determination. There can be no assurance Nasdaq would grant any such request for continued listing. The Compa”

NOCERA, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(2)(A), 5605(c)(4)).

“July 31, 2023, Nocera, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) therein stating that due to the resignation of Yih-Yu (“Grace”) Lei from the Company’s Audit Committee of the Board of Directors (“Board”), the Company no longer complies with Nasdaq’s audit committee requirement as set forth in Listing Rule 5605. As previously reported by the Company on a Current Report on Form 8-K filed with the Securities Exchange Commission on July 28, 2023, Ms. Lei resigned as a member of the Board on July 27, 2023.”

ShiftPixy, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605).

“August 2, 2023, ShiftPixy, Inc. (the “Company”) received a letter (the “Nasdaq Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notifies the Company that, in view of the recent resignation of an independent director who was a member of the Company’s audit committee, the Company does not presently comply with Nasdaq’s Listing Rule 5605, which requires that a majority of the Company’s board of directors be comprised of independent directors, and that the Company has an audit committee comprised of at least three indep”

AMAZE HOLDINGS, INC. received a nyse_american compliance regained notice regarding shareholders.

“received a letter from the NYSE American stating that the Company has resolved the deficiency set forth in the Notice and has regained compliance with the NYSE American’s audit committee composition requirements. The Notice had no immediate effect on the listing or trading of the Company’s common stock and the common stock continues to trade on the NYSE American under the symbol “VINE”. In accordance the rules of the NYSE American, the Company issued a press release on July 31, 2023, announcing that it had received the Notice.”

EVgo Inc. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605(c)(2)(A)).

“August 2, 2023, EVgo Inc. ( “ EVgo ” or the “ Company ”) notified the Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company is not in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A) solely due to a vacancy on the Audit Committee resulting from the leadership transition described in”

Rose Hill Acquisition Corp received a nasdaq delisting notice notice regarding other (rules 5550(a)(4)).

“July 26, 2023, the Company received a delisting determination letter (the “Determination Letter”) from the Staff notifying the Company that (i) it had not regained compliance with Nasdaq Listing Rule 5550(a)(4) requiring a minimum of 500,000 publicly held shares and (ii) the Company’s Class A ordinary shares, warrants and units are subject to delisting from The Nasdaq Capital Market. The Determination Letter further noted that, unless the Company requests an appeal of the Staff’s determination with the Nasdaq Hearings Panel (the “Panel”), trading of the Company’s Class A ordinary shares, war”

Canna-Global Acquisition Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A)).

“not regained compliance with the Market Value of Listed Securities (“MVLS”) Standard, since the Company’s common stock, par value $0.000001 per share (the “Common Stock”), was below the $50 million minimum MVLS requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A) (the “MLVS Rule”) and had not been at least $50 million for the proceeding 30 consecutive trading. As previously disclosed on Form 8-K filed on January 30, 2023, the Staff initially notified the Company on January 24, 2023 that the minimum MVLS for the Company’s Common Stock was below”

Cingulate Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 28, 2023, the Company received a written notice (the “Notice”) from the Staff indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock and warrants from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company’s common stoc”

Cingulate Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“July 28, 2023, the Company received a written notice (the “Notice”) from the Staff indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock and warrants from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company’s common stoc”

AIRWA INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“least $2.5 million (the “ Minimum Stockholders’ Equity Requirement ”). As reported in its Form 10-Q, the Company’s stockholders’ equity as of January 31, 2023 was approximately $(11.7) million. In addition, the Company did not meet the alternatives of listed securities or net income from continuing operations as of the date of the Letter. According to the”

Firsthand Technology Value Fund, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C)).

“July 28, 2023, Firsthand Technology Value Fund, Inc. (the “Fund”) received a letter (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) indicating that, based on the Fund’s market value of publicly held shares for the last 31 consecutive business days, the Fund no longer meets the requirement to maintain a minimum market value of publicly held shares of $5,000,000, as set forth in Nasdaq Listing Rule 5450(b)(1)(C). The Notice provides the Fund with a grace period of 180 calendar days, or until January 24, 2024, to regain compliance with the listing rule. If at any time during this grace per”

ATHERSYS, INC / NEW received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“July 28, 2023, Athersys, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per share for 30 consecutive business days for the period of June 14, 2023 through July 27, 2023. The Notice does not impact the listi”

Ascent Solar Technologies, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii), 5550(b)(1)).

“July 28, 2023, the Company received notice (the “Second Notice”) from the Staff that the Staff had determined that the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days triggering application of Listing Rule 5810(c)(3)(A)(iii) which states in part: if during any compliance period specified in Rule 5810(c)(3)(A), a company’s security has a closing bid price of $0.10 or less for ten consecutive trading days, the Listing Qualifications Department shall issue a Staff Delisting Determination under Rule 5810 with respect to that security (the “Low Priced”

Elys BMG Group, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“July 25, 2023, the Company received written notice (the “Notice”) from Nasdaq stating that the Company has not complied with the Minimum Bid Price Rule. The Notice indicated that the Company’s common stock would be suspended from trading on Nasdaq unless the Company requests a hearing before a hearings panel by August 1, 2023. The Company intends to timely request a hearing, which will stay any trading suspension of the Company’s common stock until completion of the Nasdaq hearing process and expiration of any additional extension period granted by the panel following the hearing. The Company”

MIND TECHNOLOGY, INC received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(ii), 5800).

“and registration on Nasdaq. The Company intends to appeal such determination by submitting a hearing request to a Hearings Panel (the “Panel”), prior to the deadline at 4:00 p.m. Eastern Time on August 1, 2023 noted in the Delisting Letter, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. Such hearing request will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. At the hearing, the Company plans to note that at its annual meeting of stockholders, to be held on August 30, 2023 (the “2023 Annual Meeting”)”

Sagaliam Acquisition Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“July 25, 2023 due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the “ Form 10-Q ”). The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “ SEC ”). The Notice states that the Company has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rules. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the”

Transcode Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“July 26, 2023, the Company received a Delisting Determination Letter from the Staff advising the Company that the Staff had determined not to accept the Company’s Compliance Plan, and that the Company’s request for an extension had been denied. If, in accordance with Nasdaq Listing Rule 5815(a), the Company requests a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s decision, such request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. If the Company does not request a hearing t”

Spectral AI, Inc. received a nasdaq delisting notice notice regarding shareholders (rules 5550(a)(4)).

“23, Rosecliff Acquisition Corp I (the “ Company ”) was notified by the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) that the Staff had granted the Company’s request for an extension through July 21, 2023, to regain compliance with Nasdaq Listing Rule 5550(a)(4), which requires the Company to have a minimum of 500,000 publicly held shares for continued listing on The Nasdaq Capital Market. The Company did not regain compliance by July 21, 2023, and, on July 24 2023, the Staff notified the Company that its securities would be delisted unless the C”

Assure Holdings Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(G)).

“July 25, 2023, Assure Holdings Corp. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Notice”). The Notice has no immediate effect on the continue”

Valion Bio, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).

“July 24, 2023, as expected, the Company received a new notification letter from the Listing Qualifications Department of Nasdaq notifying the Company that, as of July 21, 2023, the Company’s common stock had a closing bid price of $0.10 or less for ten consecutive trading days and that, consistent with Nasdaq Listing Rule 5810(c)(3)(A)(iii), the Staff has determined to delist the Company’s common stock from the Nasdaq Capital Market. The notice further provides that the Company has until July 31, 2023 to appeal the Staff’s decision. On July 27, 2023, the Company submitted a request for a heari”

NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“July 20, 2023, the Company received a written notification (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities (“MVLS”) because the Company has not maintained a minimum MVLS of $50,000,000 for the last thirty-three (33) consecutive business days. Nasdaq’s Notice has no immediate effect on the listing of the common stock on The Nasdaq Global Market and, at this time, the common stock will continue to trade on The Nasdaq Global Market under the symbol “NRXP”. Pursua”

CEMTREX INC received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 25, 2023, the Company received a Notice of Staff Determination from the Listing Qualifications Department of Nasdaq notifying the Company that its Series 1 Preferred Stock had not gained compliance and would be suspended from trading at the opening of business on August 3, 2023. The Company has requested a hearing regarding the delisting which will stay the suspension and filing of Form 25-NSE with the Securities and Exchange Commission (the “SEC”). The Company intends to continue actively monitoring the bid price for its Series 1 preferred stock between now and the hearing date and will”

CEMTREX INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 29, 2022, Cemtrex, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s Series 1 preferred stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer met the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). On January 26, 2023, the Compan”

Eiger BioPharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“July 26, 2023, Eiger BioPharmaceuticals, Inc. (“Eiger”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying Eiger that, for the last 30 consecutive business days, the bid price for Eiger’s common stock, par value $0.001 per share (the “Common Stock”), closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Pe”

NOS4-1, Inc. received a nyse_american delisting notice notice regarding other (rules 1003(c)(iii)).

“July 24, 2023, the Company received written notice from the staff of NYSE Regulation that, as a result of the Cases and in accordance with Section 1003(c)(iii) of the NYSE American Company Guide, NYSE Regulation has determined to commence proceedings to delist the common stock of the Company, par value $0.01 per share, from the NYSE American LLC (“ NYSE American ”). The Company does not intend to appeal NYSE Regulation’s determination. Trading of the Company’s common stock on the NYSE American was suspended on July 24, 2023, and the delisting will be effective 10 days after the NYSE American f”

Liberty Resources Acquisition Corp. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(3)(C)).

“July 24, 2023, Liberty Resources Acquisition Corp., a Delaware corporation (the “ Company ”), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that since the Company’s Market Value of Publicly Held Shares was less than $15 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5450(b)(3)(C), which requires the Company to maintain a Market Value of Publicly Held Shares of at least $15 million (the “ MVPHS Notice ”). The MVPHS Notice additionally ind”

OceanTech Acquisitions I Corp. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“July 25, 2023, the Company received written notice (the “ Delisting Letter ”) from Nasdaq that the Company has not regained compliance with Nasdaq Listing Rule 5550(b)(2) for the MVLS within the Compliance Period in accordance with Nasdaq Listing Rule 5810(c)(3)(C) . Accordingly, unless the Company requests an appeal of this determination, the Company’s securities will be delisted from The Nasdaq Capital Market, trading of the Company’s common stock will be suspended at the opening of business on August 3, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission to rem”

Pivotal Investment Corp III received a nasdaq noncompliance notice notice regarding other (rules 802.01B).

“July 21, 2023, the NYSE Office of General Counsel notified the Company that the Committee had determined to affirm the Staff’s decision to delist the Company’s Class A Common Stock and Units from the NYSE. On July 21, 2023, the Staff filed a Form 25 with the Securities and Exchange Commission (the “SEC”) to remove the Company’s Class A Common Stock and Units from listing and registration on the NYSE. The delisting will be effective 10 days following the date the Form 25 was filed. The Company’s Class A Common Stock and Units will continue to trade on the OTC marketplaces following the delistin”

Evolve Transition Infrastructure LP received a nyse_american compliance regained notice regarding minimum bid price (rules 1003(f)(v)).

“July 25, 2023, the Partnership received notice from the NYSE informing the Partnership that it has resolved the continued listing deficiency with respect to low selling price as described in Section 1003(f)(v) of the Company Guide. As a result, the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension on the Common Units on the NYSE. Accordingly, the August 8, 2023 hearing before the Panel has been cancelled. The Common Units will commence trading on the NYSE at market open on Monday, July 31, 2023 under the symbol “SNMP.” The Partnership”

Vaxart, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“July 21, 2023, Vaxart, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per sh”

USD Partners LP received a nyse noncompliance notice notice regarding minimum bid price (rules 802.01C).

“July 26, 2023, USD Partners LP (the “Partnership”) received a notice from the New York Stock Exchange (“NYSE”) that it is not in compliance with the continued listing criteria under Section 802.01C of the NYSE's Listed Company Manual, because the average closing price of the Partnership's common units was less than $1.00 over a consecutive 30 trading-day period. Under the applicable rules of the NYSE, the Partnership will respond to the NYSE within ten business days of receipt of the non-compliance notice with respect to its intent to cure the deficiency to regain compliance with the average c”

IronNet, Inc. received a nyse noncompliance notice notice regarding audit committee (rules 303A.07(A)).

“t of accounting principles, financial statement disclosure, or any issue impacting the Audit Committee. The Company thanks Mr. Rogers for his service on the Board. After giving effect to Mr. Rogers’ resignation, on July 20, 2023 the Audit Committee no longer had three members as required by Section 303A.07(A) of the Listed Company Manual of the New York Stock Exchange (“ NYSE ”). The Company informed the NYSE of the foregoing on July 20, 2023. The Company intends to regain compliance with NYSE Listed Company Manual Section 303A.07(A) promptly.”